<DOC>
	<DOC>NCT01846299</DOC>
	<brief_summary>To evaluate the efficacy and safety of 0.5 mg Ranibizumab intravitreal injections in adult patients with visual impairment due to macular edema (ME).</brief_summary>
	<brief_title>To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Diagnosis of active ME secondary to any causes (for adult patients: except diabetic macular edema (DME), agerelated macular degeneration (AMD) and retinal vein occlusion (RVO)); BCVA must be between ≥ 24 and ≤ 83 letters; Visual loss should be mainly due to the presence of any eligible types of ME. Women of childbearing potential, Active malignancies; History of stroke less than 6 months prior to screening; Uncontrolled systemic inflammation or infection, related directly to the underlying causal disease of ME; Active diabetic retinopathy, active ocular/periocular infectious disease or active severe intraocular inflammation; Any type of advanced, severe or unstable ocular disease or its reatment; ME with a high likelihood of spontaneous resolution. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Vision Impairment</keyword>
</DOC>